| | | | | | | | Welcome to Editors' (re)View, a feature where the Pharma Manufacturing editors handpick notable pharma world happenings that deserve some extra consideration. See what you may have missed this week in pharma. |
|
|
|
| |
| | |
|
|
| | | | | Alecensa is now the first and only ALK inhibitor approved for people with ALK-positive early-stage NSCLC who have undergone surgery to remove their tumor. |
|
|
| The NaV1.8 inhibitor also nabbed Breakthrough Therapy designation for diabetic peripheral neuropathy pain. |
|
|
|
| |
| | |
|
|
| | | | Sponsored | | Discover how Blue Mountain's Regulatory Asset Manager (RAM) propelled AmplifyBio, a leading Contract Research Organization (CRO), into a paperless future. |
|
|
|
| |
| | |
|
|
| | |
|
| | |
|
